MONTREAL, QUEBEC, August 30, 2022 – Valeo Pharma Inc. (TSX: VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, today announced the appointment of Mr. Kyle Steiger to the role of Senior Vice-President and Chief Commercial Officer (“CCO”).
Kirkland, Quebec-based Valeo Pharma will be responsible for all commercial and medical activities for ALLERJECT in Canada for an initial period of 10 years
MONTREAL, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Valeo Pharma Inc. (CSE:VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo Pharma” or the “Company”),na Canadian pharmaceutical company, is pleased to announce that in nconnection with its previously announced bought deal private placement nof convertible unsecured debentures (the “Offering”), nthe Company and Desjardins Capital Markets, as lead underwriter and solenbookrunner, together with a syndicate of underwriters (collectively, nthe “Underwriters”), have agreed to increase the size nof the Offering from $10,000,000 to $15,000,000 aggregate principal namount of convertible unsecured debentures of the Company (the “Debentures”).
MONTREAL, QUEBEC , November 3, 2021 – Valeo Pharma Inc. (CSE:VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, today announced that it has successfully entered into a Product Listing Agreement (“PLA”) with Alberta Minister of Health, for the listing and public reimbursement of Enerzair Breezhaler and Atectura Breezhaler, its two innovative asthma therapies, on the Alberta Drug Benefit list effective November 1, 2021.